SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Acumen Pharmaceuticals, a leading pre-clinical biotech company in Alzheimer’s therapeutics, today announced that it has joined the Neurotechnology Industry Organization (NIO) as a charter member. As a part of the newly formed NIO, the company will work along side other leading pharmaceutical, medical device and diagnostic companies as well as major academic brain research centers and patient advocacy groups to accelerate the development of treatments and cures for brain and nervous system diseases.
